NASDAQ:HSCS

Heart Test Laboratories (HSCS) Stock Forecast, Price & News

$0.44

+0.02 (+4.17%)

(As of 04:20 PM ET)

Compare

Today's Range: $0.41
▼
$0.46
50-Day Range: $0.38
▼
$0.97
52-Week Range: $0.30
▼
$3.95

Volume: 38,130 shs
Average Volume: 940,053 shs
Market Capitalization: $4.80 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $3.15

Heart Test Laboratories MarketRank™ Forecast

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 615.9% Upside
$3.15 Price Target
Short Interest: Healthy
0.54% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 1.59
Based on 3 Articles This Week
Insider Trading: N/A
Proj. Earnings Growth: N/A

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.16 out of 5 stars

3.5

Analyst's Opinion

Consensus Rating
Heart Test Laboratories has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $3.15, Heart Test Laboratories has a forecasted upside of 615.9% from its current price of $0.44.
Amount of Analyst Coverage
Heart Test Laboratories has received no research coverage in the past 90 days.

5.0

Short Interest

Percentage of Shares Shorted
0.54% of the float of Heart Test Laboratories has been sold short.
Short Interest Ratio / Days to Cover
Heart Test Laboratories has a short interest ratio ("days to cover") of 0.4, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in Heart Test Laboratories has recently decreased by 10.41%, indicating that investor sentiment is improving significantly.

0.0

Dividend Strength

Dividend Yield
Heart Test Laboratories does not currently pay a dividend.
Dividend Growth
Heart Test Laboratories does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for HSCS.

3.1

News and Social Media Coverage

News Sentiment
Heart Test Laboratories has a news sentiment score of 1.59. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.68 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 3 news articles for Heart Test Laboratories this week, compared to 0 articles on an average week.
Search Interest
Only 1 people have searched for HSCS on MarketBeat in the last 30 days. This is a decrease of -67% compared to the previous 30 days.

0.8

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Heart Test Laboratories insiders have not sold or bought any company stock.
Percentage Held by Insiders
14.60% of the stock of Heart Test Laboratories is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
Only 16.68% of the stock of Heart Test Laboratories is held by institutions.

0.0

Earnings and Valuation

Price to Earnings Ratio vs. the Market
The P/E ratio of Heart Test Laboratories is -0.66, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Heart Test Laboratories is -0.66, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

See Top Rated MarketRank™ Stocks Here

About Heart Test Laboratories (NASDAQ:HSCS) Stock

Heart Test Laboratories, Inc., a medical technology company, provides cardiovascular diagnostic devices. The company offers MyoVista wavECG, a resting 12-lead electrocardiograph (ECG) to provide diagnostic information related to cardiac dysfunction, as well as conventional ECG information. It serves clinics, doctor's offices, urgent care centers, and hospitals. The company was incorporated in 2007 and is headquartered in Southlake, Texas.

HSCS Price History

30 days | 90 days | 365 days | Advanced Chart

HSCS Stock News Headlines

September 25, 2023 | finance.yahoo.com

HeartSciences to Participate in the Maxim Group Virtual Tech Conference Series: Emerging Growth in A.I.

September 21, 2023 | finance.yahoo.com

HeartSciences Signs Definitive Agreements with the Icahn School of Medicine at Mount Sinai to Commercialize Artificial Intelligence Cardiovascular Algorithms

September 29, 2023 | Chaikin Analytics (Ad)

This Stock Could Go Up 66% or More.

Marc Chaikin built the system that isolated NVDA before it became the best-performing stock of 2023. Click here to get his latest buy. More here.

September 14, 2023 | finance.yahoo.com

HeartSciences Reports First Quarter Fiscal 2024 Financial Results

September 11, 2023 | finance.yahoo.com

HeartSciences Named Electrocardiography Advancement Specialists of the Year 2023 - USA in the Global Health & Pharma Excellence Awards

August 31, 2023 | finance.yahoo.com

HeartSciences Signs Distribution Agreement with FJ Medical, Denmark

August 24, 2023 | finance.yahoo.com

HeartSciences’ MyoVista® wavECGTM Selected to be used in Irish Heart Screening Evaluation

August 24, 2023 | finance.yahoo.com

HeartSciences’ MyoVista® wavECGTM Selected to be used in Irish Heart Screening Evaluation

September 29, 2023 | Chaikin Analytics (Ad)

This Stock Could Go Up 66% or More.

Marc Chaikin built the system that isolated NVDA before it became the best-performing stock of 2023. Click here to get his latest buy. More here.

August 17, 2023 | finance.yahoo.com

HeartSciences Announces Further Expansion of Artificial Intelligence (AI) Patent Portfolio

July 19, 2023 | finanznachrichten.de

Heart Test Laboratories, Inc.: HeartSciences Provides Business Update and Reports Fiscal 2023 Financial Results

July 19, 2023 | finance.yahoo.com

HeartSciences Provides Business Update and Reports Fiscal 2023 Financial Results

May 17, 2023 | finance.yahoo.com

HeartSciences Named as a Top 10 Healthcare Artificial Intelligence Solutions Provider 2023 by Healthcare Tech Outlook Magazine

May 8, 2023 | finance.yahoo.com

HeartSciences to Participate at the Inaugural EF Hutton Global Conference

April 17, 2023 | finance.yahoo.com

HeartSciences to Present at the Planet MicroCap Showcase: VEGAS 2023

March 18, 2023 | finance.yahoo.com

Heart Test Laboratories Reports Third Quarter 2023 Earnings

March 16, 2023 | msn.com

Heart Test Laboratories GAAP EPS of -$0.16 beats by $0.02, revenue of $1.95M

February 7, 2023 | finance.yahoo.com

HeartSciences CEO Invited as Featured Guest on The Big Biz Show, February 7 at 11:45 a.m. Pacific Time

January 23, 2023 | finance.yahoo.com

Correction: HeartSciences CEO to Participate in the Healthcare IT Virtual Conference Presented by Maxim Group LLC and Hosted by M-Vest on January 25th

January 4, 2023 | finance.yahoo.com

HeartSciences Appoints David R. Wells to its Board of Directors, an Experienced Capital Markets and Finance Executive

December 16, 2022 | finanznachrichten.de

Heart Test Laboratories, Inc.: HeartSciences Provides Business Update and Reports Second Quarter Fiscal 2023 Financial Results

December 1, 2022 | finance.yahoo.com

HeartSciences and Rutgers University Announce Multi-Year Collaboration to Develop AI-based ECG Algorithms

November 28, 2022 | finance.yahoo.com

HeartSciences to Present at the 2022 RHK Disruptive Growth Conference on December 5, 2022

November 21, 2022 | finance.yahoo.com

HeartSciences to Participate at the Benchmark Discovery One-on-One Investor Conference on December 1, 2022

November 10, 2022 | finance.yahoo.com

HeartSciences’ MyoVista® Technology Used to Develop AI-ECG Algorithm to Identify Patients at High-Risk of Major Adverse Cardiovascular Events

October 25, 2022 | finance.yahoo.com

HeartSciences Granted European Patent for Proprietary Electrode and Cable Connections for Use with its AI-Based MyoVista® ECG

October 20, 2022 | finance.yahoo.com

HeartSciences Named as a Top 10 MedTech Startup 2022 by MedTech Outlook Magazine

See More Headlines

Receive HSCS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Heart Test Laboratories and its competitors with MarketBeat's FREE daily newsletter.

HSCS Company Calendar

Last Earnings: 7/19/2023
Today: 9/29/2023
Next Earnings (Estimated): 12/21/2023
Fiscal Year End: 4/30/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Surgical appliances & supplies
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:HSCS
CUSIP: N/A
CIK: 1468492
Web: heartsciences.com
Phone: 682-237-7781
Fax: N/A
Employees: 12
Year Founded: N/A

Price Target and Rating

Average Stock Price Forecast: $3.15
High Stock Price Forecast: $3.30
Low Stock Price Forecast: $3.00
Forecasted Upside/Downside: +645.7%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 2 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($0.67)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-6,350,000.00
Net Margins: N/A
Pretax Margin: -307,400.00%
Return on Equity: -4,601.51%
Return on Assets: -173.97%

Debt

Debt-to-Equity Ratio: 2.17
Current Ratio: 1.07
Quick Ratio: 0.71

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: ($0.05) per share
Price / Book: -8.45

Miscellaneous

Outstanding Shares: 10,920,000
Free Float: 9,327,000
Market Cap: $4.61 million
Optionable: Not Optionable
Beta: 4.01

13 Stocks Institutional Investors Won't Stop Buying

Which stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.

Get This Free Report

Key Executives

Mr. Andrew Simpson (Age 54)
CEO, Pres & Chairman of Directors
Comp: $264.14k

Ms. Danielle Watson (Age 41)
CFO & Treasurer
Comp: $188.75k

Mr. Mark T. Hilz (Age 64)
COO, Sec. & Director
Comp: $263.61k

Key Competitors

View All Competitors

Institutional Ownership

View All Institutional Transactions

HSCS Stock - Frequently Asked Questions

Should I buy or sell Heart Test Laboratories stock right now?: 2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Heart Test Laboratories in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" HSCS shares.
View HSCS analyst ratings or view top-rated stocks.
What is Heart Test Laboratories' stock price forecast for 2023?: 2 equities research analysts have issued 1 year target prices for Heart Test Laboratories' stock. Their HSCS share price forecasts range from $3.00 to $3.30. On average, they predict the company's share price to reach $3.15 in the next twelve months. This suggests a possible upside of 645.7% from the stock's current price.
View analysts price targets for HSCS or view top-rated stocks among Wall Street analysts.
How have HSCS shares performed in 2023?: Heart Test Laboratories' stock was trading at $0.8399 at the start of the year. Since then, HSCS shares have decreased by 49.7% and is now trading at $0.4224.
View the best growth stocks for 2023 here.
Are investors shorting Heart Test Laboratories?: Heart Test Laboratories saw a decline in short interest in the month of September. As of September 15th, there was short interest totaling 37,000 shares, a decline of 10.4% from the August 31st total of 41,300 shares. Based on an average daily trading volume, of 94,900 shares, the days-to-cover ratio is currently 0.4 days. Approximately 0.5% of the shares of the company are short sold.
View Heart Test Laboratories' Short Interest.
When is Heart Test Laboratories' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Thursday, December 21st 2023.
View our HSCS earnings forecast.
How were Heart Test Laboratories' earnings last quarter?: Heart Test Laboratories, Inc. (NASDAQ:HSCS) issued its earnings results on Wednesday, July, 19th. The company reported ($0.16) earnings per share for the quarter.

When did Heart Test Laboratories IPO?: (HSCS) raised $9 million in an IPO on Wednesday, June 15th 2022. The company issued 1,800,000 shares at a price of $4.50-$5.50 per share. The Benchmark Company served as the underwriter for the IPO.
What is Heart Test Laboratories' stock symbol?: Heart Test Laboratories trades on the NASDAQ under the ticker symbol "HSCS."
How do I buy shares of Heart Test Laboratories?: Shares of HSCS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Heart Test Laboratories' stock price today?: One share of HSCS stock can currently be purchased for approximately $0.42.
How much money does Heart Test Laboratories make?: Heart Test Laboratories (NASDAQ:HSCS) has a market capitalization of $4.61 million. The company earns $-6,350,000.00 in net income (profit) each year or ($0.67) on an earnings per share basis.
How can I contact Heart Test Laboratories?: The official website for the company is heartsciences.com. The company can be reached via phone at 682-237-7781 or via email at hscs@crescendo-ir.com.

This page (NASDAQ:HSCS) was last updated on 9/29/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial